IL6 and rheumatoid arthritis: Furthermore, the outcomes assessed in these studies are limited to general inflammatory or oxidative biomarkers (e.g., CRP, IL-6, TNF-α), which are not validated RA-specific clinical endpoints and cannot be directly extrapolated to disease activity or joint symptoms in RA.